Molecular basis of MAPK-activated protein kinase 2:p38 assembly

p38 MAPK and MAPK-activated protein kinase 2 (MK2) are key components of signaling pathways leading to many cellular responses, notably the proinflammatory cytokine production. The physical association of p38α isoform and MK2 is believed to be physiologically important for this signaling. We report the 2.7-Å resolution crystal structure of the unphosphorylated complex between p38α and MK2. These protein kinases bind “head-to-head,” present their respective active sites on approximately the same side of the heterodimer, and form extensive intermolecular interactions. Among these interactions, the MK2 Ile-366–Ala-390, which includes the bipartite nuclear localization signal, binds to the p38α-docking region. This binding supports the involvement of noncatalytic regions to the tight binding of the MK2:p38α binary assembly. The MK2 residues 345–365, containing the nuclear export signal, block access to the p38α active site. Some regulatory phosphorylation regions of both protein kinases engage in multiple interactions with one another in this complex. This structure gives new insights into the regulation of the protein kinases p38α and MK2, aids in the better understanding of their known cellular and biochemical studies, and provides a basis for understanding other regulatory protein–protein interactions involving signal transduction proteins.

[1]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[2]  M. Gaestel,et al.  In the Cellular Garden of Forking Paths: How p38 MAPKs Signal for Downstream Assistance , 2002, Biological chemistry.

[3]  Radha Akella,et al.  Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. , 2002, Molecular cell.

[4]  C. Dinarello.  Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases , 1992, Current Biology.

[5]  J. Pflugrath,et al.  The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.

[6]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[7]  Philip R. Cohen,et al.  The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2. , 1993, The Biochemical journal.

[8]  E. Nishida,et al.  Molecular recognitions in the MAP kinase cascades. , 2003, Cellular signalling.

[9]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[10]  M. Gaestel,et al.  Interleukin (IL)-6 signaling leads to phosphorylation of the small heat shock protein (Hsp)27 through activation of the MAP kinase and MAPKAP kinase 2 pathway in monocytes and monocytic leukemia cells. , 1995, Leukemia.

[11]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[12]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[13]  T. Sturgill,et al.  Creation of a Stress-activated p90 Ribosomal S6 Kinase , 2000, The Journal of Biological Chemistry.

[14]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[15]  J. Quillard,et al.  High‐level expression, activation, and subcellular localization of p38‐MAP kinase in thyroid neoplasms , 2006, The Journal of pathology.

[16]  M. Gaestel,et al.  Distinct Cellular Functions of MK2 , 2002, Molecular and Cellular Biology.

[17]  L. Tong,et al.  A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.

[18]  Philip R. Cohen,et al.  Identification of novel phosphorylation sites required for activation of MAPKAP kinase‐2. , 1995, The EMBO journal.

[19]  C. Pargellis,et al.  Catalysis and Function of the p38α·MK2a Signaling Complex , 2004 .

[20]  G. Kollias,et al.  Generation and Characterization of p38β (MAPK11) Gene-Targeted Mice , 2005, Molecular and Cellular Biology.

[21]  Matthew Brook,et al.  Edinburgh Research Explorer Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element , 2022 .

[22]  P. Bender,et al.  Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors , 1993, Annals of the New York Academy of Sciences.

[23]  M. Gaestel,et al.  Leptomycin B‐sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation , 1998, The EMBO journal.

[24]  M. Gaestel,et al.  FRET‐based detection of different conformations of MK2 , 2001, EMBO reports.

[25]  M. Gaestel,et al.  Constitutive Activation of Mitogen-activated Protein Kinase-activated Protein Kinase 2 by Mutation of Phosphorylation Sites and an A-helix Motif (*) , 1995, The Journal of Biological Chemistry.

[26]  Sam-Yong Park,et al.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 , 2004, The EMBO journal.

[27]  J. Lisnock,et al.  Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase. , 2005, Analytical biochemistry.

[28]  E. Goldsmith,et al.  The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[30]  M. Gaestel,et al.  MAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis , 2006, The Journal of Immunology.

[31]  K. Parris,et al.  Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. , 2003, Structure.

[32]  Chi‐Kuang Huang,et al.  Characterization of an Autoinhibitory Domain in Human Mitogen-activated Protein Kinase-activated Protein Kinase 2 (*) , 1995, The Journal of Biological Chemistry.

[33]  C. Lepre,et al.  Crystal Structure of the P38α-MAPKAP Kinase 2 Heterodimer* , 2007, Journal of Biological Chemistry.

[34]  B. Bresnihan,et al.  Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[35]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[36]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[37]  A. Bennett,et al.  Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab , 2004, The British journal of dermatology.

[38]  M. Madsen,et al.  Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21 , 2006, The Journal of Immunology.

[39]  E. Nishida,et al.  Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions , 2001, The EMBO journal.

[40]  M. Fitzgibbon,et al.  Structure of Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinase 2 Suggests a Bifunctional Switch That Couples Kinase Activation with Nuclear Export* , 2002, The Journal of Biological Chemistry.

[41]  C. Pargellis,et al.  Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. , 2003, Current opinion in investigational drugs.

[42]  E. Goldsmith,et al.  Docking interactions induce exposure of activation loop in the MAP kinase ERK2. , 2006, Structure.

[43]  C. Marshall,et al.  Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2 , 1998, Current Biology.

[44]  Melanie Allen,et al.  Deficiency of the Stress Kinase P38α Results in Embryonic Lethality , 2000, The Journal of Experimental Medicine.

[45]  Klaus Resch,et al.  The p38 MAP kinase pathway signals for cytokine‐induced mRNA stabilization via MAP kinase‐activated protein kinase 2 and an AU‐rich region‐targeted mechanism , 1999, The EMBO journal.

[46]  M. Gaestel,et al.  MAPKAP kinases — MKs — two's company, three's a crowd , 2006, Nature Reviews Molecular Cell Biology.

[47]  C. Huang,et al.  The primary structure of a human MAP kinase activated protein kinase 2. , 1994, Biochemical and biophysical research communications.

[48]  M. Gaestel,et al.  MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis , 1999, Nature Cell Biology.

[49]  E. Nishida,et al.  A conserved docking motif in MAP kinases common to substrates, activators and regulators , 2000, Nature Cell Biology.

[50]  P. Anderson,et al.  MK2‐induced tristetraprolin:14‐3‐3 complexes prevent stress granule association and ARE‐mRNA decay , 2004, The EMBO journal.